Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.

Higuchi, Tomoko

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. [electronic resource] - Oral surgery, oral medicine, oral pathology and oral radiology 06 2018 - 547-551 p. digital

Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't

2212-4411

10.1016/j.oooo.2018.02.010 doi


Adult
Aged
Aged, 80 and over
Bisphosphonate-Associated Osteonecrosis of the Jaw--etiology
Bone Density Conservation Agents--administration & dosage
Bone Neoplasms--drug therapy
Denosumab--administration & dosage
Diphosphonates--administration & dosage
Female
Humans
Imidazoles--administration & dosage
Japan
Male
Middle Aged
Retrospective Studies
Risk Factors
Zoledronic Acid